Otricath Platform for Solid Tumors

About Otricath

Otricath is a private, pre-revenue medical device innovator with a platform designed to revolutionize localized drug delivery for solid tumors. The company's technology promises enhanced control and safety in delivering therapeutic agents directly to the tumor site, potentially improving efficacy while reducing off-target toxicity. While initially targeting oncology via cardiovascular access routes, the platform's applicability may extend to other disease areas requiring precise regional therapy. The company appears to be in a pre-clinical or early clinical stage, as evidenced by pilot studies, and is headquartered in the major medtech hub of San Jose.

Therapeutic Areas

Other Solid Tumors (Oncology) Drugs